Baxter International Inc.announced it has signed a definitive agreement to acquire the Oncaspar (pegaspargase) product portfolio from Sigma-Tau Finanziaria S.p.A....
Sigma-Tau Pharmaceuticals, Inc., a leader in the development and commercialization of medicines for patients with rare diseases, announced that the...
Sigma Tau Pharma has announced the submission of an application to the European Medicines Agency (EMA) for use of its...
Jazz Pharmaceuticals plc has announced that the company has signed a definitive agreement with Sigma-Tau Pharmaceuticals, Inc. under which a...
Retrophin, Inc.has announced that the FDA has approved Cholbam (cholic acid) capsules, the first FDA approved treatment for pediatric and...
Merck KGaA, has announced that approvals have been secured from all relevant jurisdictions for its planned acquisition of U.S.-based life...
Primary biliary cholangitis (PBC), previously known as primary biliary "cirrhosis", is a rare autoimmune liver disease characterized by ...
Baxter International Inc. announced that it has received 510(k) clearance from the FDA for its next-generation SIGMA Spectrum Infusion Pump...
Methamphetamine (METH) is a drug with a high addictive potential that is widely abused across the world.
Baxter International is committed to enhancing patient safety during medication delivery, and highlighted compliance data showing facilities that implemented Sigma...